Encyt was founded in 2014 and has been engaged in pioneering research that has uncovered evidence  for a distinct and highly conserved inflammatory response triggered by  surgical removal of a primary breast, colorectal, or prostate tumor and  treatment with chemotherapy or radiation.  This response occurs  within a predictable time frame after cancer treatment and can trigger  accelerated regrowth of a surviving cancer cell population and induce  cancer stem cell enrichment.   This inflammatory response will lead to  the development of a metastatically competent, treatment resistant  cancer cell phenotype in the cancer cells that survive the treatment.



Based  on our discovery of the specific triggers of this process, Encyt has  focused on the development of therapeutic options to disrupt this  process at the time it is up-regulated as a rational  treatment approach against cancer.  Encyt has entered into a  collaboration with a research group from Queen’s University where we  have been conducting extensive animal studies using a unique and proprietary combination of therapeutic agents designed to disrupt the signaling pathways that we have identified as being important in facilitating this process.    We  have been able to achieve an impressive 90% reduction in the growth of a  human primary pancreatic cancer in mouse xenografts as compared with  chemotherapy alone and significantly limit the  development of metastatic disease and drug resistance.   We have also  shown even greater efficacy in the treatment of human ovarian and breast  cancer using our novel treatment approach in xenografts.



Given the outstanding success that we have seen in our experimental approach in xenografts, Encyt  has filed with Health Canada a proposal to test our therapeutic  approach in a phase 1/2 clinical trial in patients with pancreatic  cancer.   Given the incurable nature of this deadly  disease and the lack of effective treatment options in these patients,  we have decided to focus our initial efforts on this most difficult to  treat malignancy anticipating fewer regulatory hurdles in gaining trial  approval.  We think our treatment approach may prove effective in a  variety of malignancies, but for now we are focusing our efforts on this  very difficult to treat and highly lethal malignancy.



Encyt’s  main focus at present is to test our novel and proprietary therapeutic  approach in a human clinical trial.  However, based on our research  discoveries, Encyt has also started to work in the area of liquid biopsy. We  are developing a blood test that can predict the effectiveness of a  given chemotherapeutic regimen on the basis of the level of expression  of several distinct cytokines.  We believe this work has  enormous potential to serve as a valuable predictive tool to help guide  treatment decisions made by medical oncologists.  



Encyt is  funded through a small group of angel investors, as well as support from  various government and philanthropic organizations.  In early 2017,  Encyt hopes to initiate its first human clinical trial for treatment of  pancreatic cancer.   The company is currently seeking additional funds  for expansion of human clinical trials and eventual commercialization or  licensing.  Additionally, new funds requested will be used to begin  further development of our discoveries in the area of liquid biopsy.

Scientific Publications and Media

Cancer Treatments Transform Residual Cancer Cell Phenotype

http://www.ncbi.nlm.nih.gov/pubmed/21214935


Revisiting Perioperative Chemotherapy: The Critical Importance of Targeting Residual Cancer Prior to Wound Healing
http://www.ncbi.nlm.nih.gov/pubmed/19383172


Patent Pending: "Prevention of Metastasis and Recurrence after Primary Cancer Treatment" (2015)